)
Denali Therapeutics (DNLI) investor relations material
Denali Therapeutics Stifel 2025 Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic vision and technology
Focused on crossing the blood-brain barrier and defeating neurodegeneration using transport vehicle technology, leveraging transferrin receptor for CNS delivery.
Pipeline progress includes late-stage and new clinical programs, with regulatory filings for multiple modalities.
Three main franchises: enzyme transport vehicle (ETV), oligonucleotide, and protein replacement therapies.
ETV franchise includes programs for Hunter syndrome (BLA under review), Sanfilippo (accelerated approval planned), Pompe (entering trials), and FTD granulin.
First oligonucleotide program targeting MAPT (tau) has entered the clinic, with an amyloid beta program close to filing.
Regulatory and clinical updates
Hunter syndrome BLA review delayed by FDA due to a clerical error, shifting PDUFA date to April 5, but engagement remains positive and collaborative.
Launch preparations underway with a small, ready field team for Hunter and Sanfilippo, with plans to expand for Pompe.
Market access strategy divides global opportunity into thirds: US, ex-US accessible with accelerated approval, and Europe requiring additional clinical endpoints.
Sanfilippo program completed Phase 1/2 enrollment (20 patients), with data expected 49 weeks post-September and BLA filing preparation underway.
Sanfilippo manufacturing is in-house, marking a shift from previous reliance on external partners.
Clinical data and trial design
Robust biomarker effects observed in Sanfilippo and Hunter programs, with neurocognitive, behavioral, and hearing data maturing.
Hunter confirmatory trial uses active comparator and co-primary endpoints of CSF heparan sulfate and Vineland behavioral scale; enrollment to complete by year-end, with trial completion expected in 2027.
Sanfilippo trial likely to use natural history as comparator due to lack of standard of care, with similar endpoints as Hunter.
Pompe program addresses unmet needs in both neuro and muscle domains, with further strategy details to be shared at Analyst Day.
Next Denali Therapeutics earnings date
Next Denali Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)